Silvant Capital Management LLC Purchases Shares of 19,584 Insmed, Inc. $INSM

Silvant Capital Management LLC purchased a new stake in Insmed, Inc. (NASDAQ:INSM) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 19,584 shares of the biopharmaceutical company’s stock, valued at approximately $3,408,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in INSM. CIBC Private Wealth Group LLC grew its holdings in Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 53 shares during the period. CoreCap Advisors LLC purchased a new stake in Insmed in the 4th quarter valued at about $27,000. GraniteShares Advisors LLC purchased a new stake in Insmed in the 4th quarter valued at about $30,000. Raiffeisen Bank International AG purchased a new stake in Insmed in the 4th quarter valued at about $32,000. Finally, RiverPark Advisors LLC purchased a new stake in Insmed in the 3rd quarter valued at about $38,000.

Insiders Place Their Bets

In other Insmed news, CEO William Lewis sold 10,699 shares of the company’s stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $143.97, for a total value of $1,540,335.03. Following the transaction, the chief executive officer directly owned 301,185 shares of the company’s stock, valued at $43,361,604.45. This represents a 3.43% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Roger Adsett sold 88,060 shares of the company’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $164.63, for a total value of $14,497,317.80. Following the completion of the transaction, the chief operating officer directly owned 106,810 shares in the company, valued at approximately $17,584,130.30. The trade was a 45.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 160,482 shares of company stock valued at $24,438,193. Company insiders own 2.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. Wells Fargo & Company lowered their price target on Insmed from $177.00 to $160.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Bank of America boosted their target price on Insmed from $211.00 to $213.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. JPMorgan Chase & Co. decreased their target price on Insmed from $180.00 to $179.00 and set an “overweight” rating for the company in a report on Monday, June 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Insmed in a report on Tuesday, April 21st. Finally, Mizuho boosted their target price on Insmed from $204.00 to $206.00 and gave the stock an “outperform” rating in a report on Wednesday, March 25th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Insmed presently has an average rating of “Moderate Buy” and an average target price of $212.50.

Insmed Stock Down 0.4%

NASDAQ INSM opened at $97.46 on Tuesday. The stock has a market cap of $21.12 billion, a PE ratio of -16.95 and a beta of 0.79. Insmed, Inc. has a fifty-two week low of $90.39 and a fifty-two week high of $212.75. The business has a 50 day moving average price of $123.25 and a two-hundred day moving average price of $150.13. The company has a quick ratio of 4.10, a current ratio of 4.47 and a debt-to-equity ratio of 0.80.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.14. The firm had revenue of $305.96 million during the quarter, compared to analysts’ expectations of $300.81 million. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.Insmed’s quarterly revenue was up 229.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.42) EPS. As a group, sell-side analysts predict that Insmed, Inc. will post -2.54 EPS for the current fiscal year.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.